Day: March 4, 2025

* Board Declares Cash Dividend* MIND CTI to Host Annual Meeting of Shareholders YOQNEAM, Israel, March 04, 2025 (GLOBE NEWSWIRE) — MIND C.T.I. LTD. – (NasdaqGM: MNDO), a leading provider of convergent end-to-end prepaid/postpaid billing and customer care product based solutions for service providers, unified communications (UC) analytics and call accounting solutions for enterprises as well as enterprise messaging solutions, today announced results for its fourth quarter of 2024 and its full year ended December 31, 2024. The following will summarize our business in the fourth quarter of 2024 and provide a more detailed review of the financial results for the quarter and for the full year. Full financial results can be found in the Company News section of our website at http://www.mindcti.com/company/news/ and in our Form 6-K. Financial...

Fourth quarter and full year 2024 gross margins improved 100 and 160 basis points while net sales were down 5.0% and 2.4%, respectively, highlighting improved portfolio profitability year over year. Fourth quarter net loss of $0.3 million was favorable $0.2 million versus last year; adjusted EBITDA1 of $7.2 million was favorable $1.1 million, or 18.7%, over the prior year quarter. Full year 2024 cash flow from operations was $22.6 million, with $24.3 million generated in the fourth quarter; Total debt declined $21.6 million during the quarter to $46.9 million; Gross Leverage Ratio1 of 1.2x decreased 0.7x during the quarter and 0.5x compared to last year. The Company’s Board of Directors authorized a new, 3-year $40 million stock repurchase program. The Company announced full year financial guidance for 2025 with net sales expected...

SPRINGFIELD, N.J., March 04, 2025 (GLOBE NEWSWIRE) — Village Super Market, Inc. (NSD-VLGEA) today reported its results of operations for the second quarter ended January 25, 2025. Second Quarter HighlightsNet income of $16.9 million, an increase of 17% compared to the second quarter of the prior year Sales increased 4.2% and same store sales increased 2.3% Same store digital sales increased 9%Year-To-Date Fiscal 2025 HighlightsNet income of $29.7 million, an increase of 14% compared to $26.1 million in the prior year-to-date period Sales increased 4.1% and same store sales increased 2.4% Same store digital sales increased 8%Second Quarter of Fiscal 2025 Results Sales were $599.7 million in the 13 weeks ended January 25, 2025 compared to $575.6 million in the 13 weeks ended January 27, 2024. Sales increased due to an increase...

GLEN ALLEN, Va., March 04, 2025 (GLOBE NEWSWIRE) — Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today provided a business update and reported its financial results for the 2024 fiscal year ended December 31, 2024. Key HighlightsSuccessful completion of AD04-103 pharmacokinetics (PK) study of AD04, corroborating bioavailability, dose proportionality, no food effect, and safety profile consistent with the use of Ondansetron.Advancement towards pivotal Phase 3 trial design supportive of ongoing partnership discussions.FDA confirmation of proposed 505(b)(2) bridging strategy leveraging the results from AD04-103—a relative bioavailability food-effect study—along...

Dosing underway in INLIGHT trial of WVE-007 in obesity with clinical data expected in 2H 2025; enrollment complete in first single dose cohort Multi-dosing ongoing in 200 mg cohort of RestorAATion-2 clinical trial of WVE-006 in AATD with data expected in 2025; second single dose cohort initiated at 400 mg On track to deliver FORWARD-53 48-week data in DMD and feedback from regulators in 1Q 2025 IND submission expected 2H 2025 for potentially registrational WVE-003 Phase 2/3 study in HD with caudate atrophy as a primary endpoint Cash and cash equivalents of $302.1 million as of December 31, 2024, with runway expected into 2027 Investor conference call and webcast at 8:30 a.m. ET today CAMBRIDGE, Mass., March 04, 2025 (GLOBE NEWSWIRE) — Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking...

Full Year revenue of $314.0 million, recurring revenue growth of 47% YoY On a constant currency basis revenue of $315.2 million, a 34% increase Adjusted EBITDA of $35.5 million (1) and Free Cash Flow of $18 million (1) for the year 2025 Revenue guidance of $410 million – $425 million 2025 Adjusted EBITDA(1)(2) guidance of $65 million – $70 million HERZLIYA, Israel, March 04, 2025 (GLOBE NEWSWIRE) — Nayax Ltd. (Nasdaq: NYAX, TASE: NYAX), a global commerce payments and loyalty platform designed to help merchants scale their business, today announced its financial results for the fourth quarter and full year ended December 31, 2024. “We are pleased to report another year of strong growth and performance for Nayax as we achieved several key milestones including significant revenue growth and margin expansion, robust operating...

Interim data from Dose 1 PBFT02 demonstrated durable, elevated CSF PGRN and early evidence of reduction in plasma NfL levels, a disease progression biomarker, as compared to published natural history Enrolled first FTD-GRN patient to be treated with Dose 2 PBFT02, 50% lower than Dose 1 Expect to report 12-month data from Dose 1 and interim safety and biomarker data from Dose 2 in 2H 2025; plan to seek regulatory feedback on FTD-GRN pivotal trial design in 1H 2026 Extended cash runway into 1Q 2027 PHILADELPHIA, March 04, 2025 (GLOBE NEWSWIRE) — Passage Bio, Inc. (Nasdaq: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today reported financial results for the fourth quarter and year ended December 31, 2024, and provided recent business highlights. “We are...

– Company achieves record revenue, gross profit margin and operating income in fiscal year 2024 – – FY24 revenue of $99.4 million increased 15.4% year-over-year excluding discontinued operations – – Fourth quarter 2024 revenue of $25.0 million increased 3.5% year-over-year and was flat sequentially – – Company ended fiscal year 2024 with $91.6 million in cash after closing private placement in December – – Merger Transactions, recent equity raise, and growth catalysts position Company for transformational 2025 – MINNEAPOLIS, March 04, 2025 (GLOBE NEWSWIRE) — Vireo Growth Inc. (“Vireo” or the “Company”) (CSE: VREO; OTCQX: VREOF), today reported financial results for its fourth quarter and fiscal year ended December 31, 2024. Key financial results are presented below in summary form with supporting commentary...